A

AbbVie

Global biopharmaceutical company developing medicines

Head Global Oncology Pipeline - Medical Affairs

Full-TimeUpdated on 10/23/2026
$248k - $471.5k/yr+ Long-term incentive program
Expert
MD
San Francisco, CA, USA+2 moreMore locations: Florham Park, NJ, USA | Lake County, IL, USA
HybridHybrid: in-office 3 days per week; Tuesday–Thursday required. Travel domestically and internationally up to 25–30%.
Biology & Biotech

About the job

Requirements
  • An M.D. or equivalent advanced degree in a relevant scientific discipline, such as oncology or hematology.
  • At least 15 years of experience in the pharmaceutical or biotechnology industry, focused on oncology, specifically hematology.
  • Demonstrated expertise in clinical development, regulatory requirements, and commercialization of oncology therapies.
  • Proven leadership experience in medical affairs, including managing direct and indirect reports, cross-functional teams, and influencing strategic direction at the senior executive level.
  • Strong scientific knowledge of solid tumor biology, clinical trial design, biomarker development, and emerging treatment modalities such as immuno-oncology, targeted therapies, and precision medicine.
  • Ability to work cross-functionally and collaborate effectively with clinical development, regulatory, commercial, and other business functions.
  • Experience presenting complex scientific information to technical and non-technical stakeholders.
  • Ability to travel domestically and internationally up to 25–30%.
Responsibilities
  • Lead global pipeline medical affairs strategy and develop differentiation across the lifecycle, using market insights to shape the therapeutic area pipeline.
  • Shape initial value and evidence strategy and initiate evidence-generation plans using insights from payors, patients, and physicians; direct the pipeline execution team to ensure the strategy is implemented by enterprise research medical science liaisons.
  • Collaborate with counterparts in international therapeutic areas, the global therapeutic area business unit, and development.
  • Represent the therapeutic area in pipeline governance when aligned with the therapeutic area business unit head.
  • Work with operations and medical engagement teams to operationalize pipeline strategy.
  • Lead and oversee pipeline, including business development, medical, value, and evidence strategy development across all disease areas within the therapeutic area for United States and international markets, covering indications and brands up to 24–36 months before launch in any geography.
  • Drive differentiated medical, value, and evidence strategies from discovery by using insights from United States and international markets.
  • Coordinate across therapeutic areas so their pipeline strategies form a coherent company-wide pipeline strategy.
  • Ensure insights from healthcare professionals, patients, and payors are incorporated into development programs to accelerate and differentiate clinical and commercialization strategies, including streamlined patient data collection and patient finding.
  • Co-create brand strategies for all assets and ensure United States and international market insights are embedded in them.
  • Represent medical affairs in pipeline-related governance as the primary contact for commercial and development counterparts.
  • Serve as the final decision maker before the business unit head for pipeline-related strategy and decisions.
  • Manage pipeline resources, redirecting the pipeline team to enterprise-critical assets across the lifecycle as needed, starting as early as discovery.
  • Ensure effective handover to United States and international inline and launch teams, onboarding with relevant therapeutic areas to share pipeline strategy insights and approaches and minimize duplicated effort.
  • Lead cross-functional gap assessments and integrated evidence planning, collaborating with Value and Evidence.
  • Define the strategy for enterprise research medical science liaisons in the United States and affiliates, using pipeline insights to develop priorities and shape tactical plans.
  • Coordinate with the United States medical engagement pipeline execution group to drive execution.
  • Collaborate with United States medical engagement to track impact-focused key performance indicators and reshape pipeline strategy based on impact or best practices.
Desired Qualifications
  • Familiarity with advanced cancer treatment modalities such as chimeric antigen receptor T-cell therapies, combination therapies, and immuno-oncology.
  • A strong publication and scientific communication track record in oncohematology, including contributions to peer-reviewed journals and major oncology conferences.
  • Experience managing global medical affairs activities across multiple geographic regions, with a focus on global strategy and the United States region.

About the company

AbbVie is a global biopharmaceutical company that develops and sells medicines to treat serious health conditions. Its portfolio spans immunology, oncology, virology, neuroscience, and aesthetics, with products designed to modulate the immune system, target disease pathways, or support medical aesthetics. AbbVie compounds its products through a heavy emphasis on research and development, investing billions to build a steady pipeline of new therapies. Its medicines are brought to market by selling to healthcare providers, hospitals, and clinics, and in some cases directly to patients via prescriptions. The company differentiates itself through a wide, globally distributed product line, substantial R&D investment, and a commitment to sustainability and patient care, including science-based targets. AbbVie’s goal is to improve patient outcomes by delivering effective treatments for unmet medical needs while pursuing long-term, responsible growth across healthcare markets.

Company Size

10,001+

Company Stage

IPO

Headquarters

North Chicago, Illinois

Founded

1888

Get referred to AbbVie

See people who can refer or advise you

Simplify Jobs

Simplify's Take

What believers are saying

  • Apogee acquisition closed in 2026, expanding AbbVie’s immunology pipeline beyond Skyrizi and Rinvoq.
  • EU approvals for RINVOQ and EPKINLY in September 2026 broaden ex-U.S. revenue.
  • JUVMO launches in October 2026, adding a fresh neuroscience revenue line.

What critics are saying

  • Humira, Skyrizi, and Rinvoq concentration keeps AbbVie exposed if immunology growth slows in 2027.
  • Niaspan antitrust MDL and Biocell ALCL settlements carried $1.7 billion litigation accrual by June 2026.
  • Generic ubrogepant and atogepant suits threaten Ubrelvy and Qulipta exclusivity within years.

What makes AbbVie unique

  • Skyrizi and Rinvoq anchor AbbVie’s post-Humira immunology franchise across 11 EU RINVOQ indications.
  • JUVMO’s September 28, 2026 FDA approval gives AbbVie first-in-class Parkinson’s D1/D5 therapy.
  • AbbVie pairs blockbuster cash flows with Apogee, Iambic, and Valkai deal-making.

Help us improve and share your feedback! Did you find this helpful?

Benefits

  • Remote Work Options
  • Flexible Work Hours
  • Professional Development Budget

Growth & Insights and Company News

Headcount

6 month growth

4%

1 year growth

5%

2 year growth

5%
Yahoo Finance
Oct 22nd, 2026
Abbott stock: $247,767 in shares yields $500 a month in dividends ahead of Q3 earnings

Abbott Laboratories will report third-quarter earnings before the market opens on Wednesday, October 21. Analysts expect earnings of $1.41 per share, up from $1.30 a year earlier, and revenue of $12.99 billion, against $11.37 billion last year. On October 16, TD Cowen analyst Joshua Jennings reiterated a Buy rating and a $135 price target. Abbott pays a quarterly dividend of 63 cents per share ($2.52 a year), a yield of 2.42%. To earn $500 a month ($6,000 a year) from dividends alone, an investor would need about 2,381 shares, or roughly $247,767.

Yahoo Finance
Oct 21st, 2026
Retirees swap Social Security for 5 dividend stocks yielding up to 6.64%

Retirees looking for income beyond Social Security are turning to dividend stocks. The 2027 cost-of-living adjustment is tracking toward 3.3%, and five companies from different industries were screened for dividend safety first, then yield. Verizon yields 6.64% and Altria 6.17%. Verizon's free cash flow guidance of $21.94 billion to $22.14 billion covers its roughly $11.76 billion annual dividend. Altria's payout is about 79% of the low end of its 2026 earnings guidance. Realty Income pays monthly at a 5.99% yield and has raised its dividend 115 consecutive quarters. Enbridge yields 5.95%. AbbVie yields 2.48%, but its quarterly dividend has grown from $0.40 in 2013 to $1.73 in 2026. Risks include satellite competition for Verizon, falling cigarette volumes for Altria, and currency swings for Enbridge.

Yahoo Finance
Oct 19th, 2026
Merck and AbbVie shares jump 39% and 24% in 2026 as dividend picks for a decade

Healthcare stocks are rebounding in 2026, led by Merck and AbbVie. Merck shares have climbed 39% and AbbVie's 24%, against about 12% for the S&P 500. Merck's second-quarter revenue rose 5% to $16.6 billion, beating Wall Street estimates. Keytruda sales hit $8.4 billion, though the drug will likely lose patent exclusivity by 2028. A subcutaneous version, Keytruda Qlex, may help retain market share. Merck's forward dividend yield is 2.3%. AbbVie's revenue grew 10.2% to almost $17 billion, with adjusted earnings per share up 22.9% to $3.65. Skyrizi and Rinvoq sales each rose about 24%, and neither faces US competition until 2033 and 2037 respectively. AbbVie has raised its dividend for 54 straight years, including its time as part of Abbott Laboratories.

Yahoo Finance
Oct 19th, 2026
Buffett warns of a "gambling mood" in markets; Vertex, Eli Lilly and AbbVie built to weather a drop

Warren Buffett, now Berkshire Hathaway's chairman emeritus, gave his bluntest warning yet at the May shareholder meeting. "We've never had people in a more gambling mood than now," he told CNBC, pointing to individuals rushing into short-term options and betting on markets. He said this behaviour is risky for those taking part and may threaten the market, possibly leading to a drop. The article suggests drugmakers as defensive picks, since patients need treatments in any economy. Vertex Pharmaceuticals leads in cystic fibrosis treatment. Eli Lilly's tirzepatide drugs, Mounjaro and Zepbound, earned more than $14 billion of its $23 billion quarterly revenue. AbbVie's Rinvoq and Skyrizi each grew 24%, and it has raised its dividend for more than 50 consecutive years.

Yahoo Finance
Oct 18th, 2026
Ken Griffin's Citadel boosts AbbVie stake 546% in Q2 as defensive dividend play

Citadel founder and chief executive officer Ken Griffin made healthcare his biggest bet in the second quarter. He bought 2.7 million AbbVie shares, a 546% increase from the previous quarter, and added 6.7 million shares of Abbott Laboratories, up 349%. He also raised his Eli Lilly stake by 291%, the third-biggest individual equity add. The moves suggest a defensive stance. Healthcare stocks tend to hold up in downturns, and both AbbVie and Abbott are Dividend Kings, having raised dividends for 54 straight years. AbbVie yields 2.65% and trades at 16 times forward earnings. In the second quarter, its adjusted earnings rose 23% and net revenue rose 10%. Some 75% of analysts covering the stock rate it a buy.